



Request under Freedom of Information Act 2000

Request Ref: NGFOI 17/18: 557

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 09/03/2018.

I am pleased to be able to provide you with the following information:

Do you currently offer a biomarker testing for the following, as of the beginning of 2018?

PD-L1 in NSCLC

Yes, but send out PD-L1 testing to another laboratory
Laboratory samples are sent to Queen Elizabeth Hospital Birmingham - Tissue blocks and slides sent.

ALK in NSCLC

Yes, but send out ALK testing to another laboratory
Laboratory samples are sent to Queen Elizabeth Hospital Birmingham - Tissue blocks

BRAF in Melanoma

Yes, but send out BRAF testing to another laboratory
Laboratory samples are sent to Source BioScience - Tissue block

2. Is predictive biomarker testing conducted at the same lab (or similar location such as in same building) as the initial cytological and histological (H&E stain) assessment, or is this done at a different site?

IHC

Yes, done at same lab or site

FISH /ISH/ NGS / P

No, sent to another lab or site
Laboratory samples are sent to Heart of England Trust Birmingham - Tissue blocks and slides sent.

3. Is biomarker testing performed reflexively or upon request for the following biomarkers?

PD-L1 in NSCLC

Reflexively (i.e. prior to starting 1L treatment)
Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol for PD-L1 testing in lung cancer patients
Multi-marker panel (i.e. multiple biomarkers, one test)
Sequential single gene (i.e. one biomarker, one test)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested.

ALK for NSCLC

Reflexively (i.e. prior to starting 1L treatment)

Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol for ALK testing in lung cancer patients

Multi-marker panel (i.e. multiple biomarkers, one test)

Sequential single gene (i.e. one biomarker, one test)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested.

BRAF in Melanoma

Reflexively (i.e. prior to starting 1L treatment)

Upon request (i.e. case by case after disease progression)

If reflexively – What is the laboratory protocol – What is the laboratory protocol for BRAF testing in melanoma patients

Multi-marker panel (i.e. multiple biomarkers, one test)

Sequential single gene (i.e. one biomarker, one test)

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested.

4. Which of the following biomarkers are assessed in lung cancer patients in your laboratory? (please select all that apply)

ALK Not performed in house

EGFR Not performed in house

PDL-1 Not performed in house

5. Which of the following testing platforms are used at this this laboratory? (please select all that apply)

FISH Not performed in house

IHC Performed in house

6. What IHC staining platform(s) are used in the laboratory for biomarker testing? (please select all that apply)

Leica Bond III IHC analyser

7. What type of test does the institution prefer to use for biomarker-predictive IHCs?

What is the main factor in this decision?

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested.

8. Does your lab / trust seek separate reimbursement from NHS under the “high-cost medicines and tests” provision for biomarker tests that have been excluded from tariff?

Yes

9. What is the number of samples being tested (or sent-out) are tested for the following biomarkers?

ALK

4 (per month)

EGFR

5 (per month)

PD-L1

6 (per month)

BRAF

4 (per month)

10. Where are archived tissues from lung cancer patients stored?

Both On-site and Off-site

11. If on-site; how long are tissues stored on site until transferred to other storage facility?

>2 yrs

12. What is the typical turn-around time from tissue/specimen extraction to the report of biomarker testing results in lung cancer patients?

>2 weeks

13. How are the following biomarker testing funded at your lab?

I can confirm on behalf of the Trust and in accordance with S.1 (1) of the Freedom of Information Act 2000 (FOIA) that we do not hold the information you have requested.